Barclays raised the firm’s price target on Avidity Biosciences (RNA) to $62 from $59 and keeps an Overweight rating on the shares. The firm views the company’s Q2 report as largely incremental.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Signs Manufacturing Agreement with Lonza
- Avidity Biosciences reports Q2 EPS ($1.21), consensus (96c)
- Avidity Biosciences: Promising Pipeline and Strategic Developments Drive Buy Rating Amid Potential Novartis Takeover Interest
- Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz
- Avidity up over 20% to $46.05 after FT report of buyout interest